392 related articles for article (PubMed ID: 22718212)
1. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
Torres A; Ramirez P; Montull B; Menéndez R
Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
[TBL] [Abstract][Full Text] [Related]
2. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
4. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
5. [Biomarkers in community acquired pneumonia - what did we learn from the CAPNETZ study?].
Krüger S; Pletz MW; Rohde G
Pneumologie; 2011 Feb; 65(2):110-3. PubMed ID: 21117019
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
[TBL] [Abstract][Full Text] [Related]
7. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
[TBL] [Abstract][Full Text] [Related]
8. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
10. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
Schuetz P; Litke A; Albrich WC; Mueller B
Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
[TBL] [Abstract][Full Text] [Related]
11. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
12. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
[TBL] [Abstract][Full Text] [Related]
13. [Biomarkers in Diagnosis, Treatment and Prognosis of Infectious Lung Diseases].
Unnewehr M; Kolditz M; Windisch W; Schaaf B
Pneumologie; 2018 May; 72(5):341-346. PubMed ID: 29046011
[TBL] [Abstract][Full Text] [Related]
14. Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ.
Krüger S; Ewig S; Kunde J; Hartmann O; Marre R; Suttorp N; Welte T;
Clin Chim Acta; 2010 Dec; 411(23-24):1929-34. PubMed ID: 20699094
[TBL] [Abstract][Full Text] [Related]
15. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in community-acquired pneumonia.
Krüger S; Welte T
Expert Rev Respir Med; 2012 Apr; 6(2):203-14. PubMed ID: 22455492
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia.
Lee JY; Hwang SJ; Shim JW; Jung HL; Park MS; Woo HY; Shim JY
Korean J Lab Med; 2010 Aug; 30(4):406-13. PubMed ID: 20805714
[TBL] [Abstract][Full Text] [Related]
19. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]